Cassava Sciences, Inc. is currently conducting two ongoing Phase 3 clinical trials for simufilam, their investigational drug for Alzheimer's disease:
- ReThink-ALZ: This trial has a 52-week treatment period and involves 804 patients.
- ReFocus-ALZ: This trial has a 76-week treatment period and involves 1,125 patients.
This morning, the company announced the discontinuation of the ReFocus-ALZ trial due to the results of the ReThink-ALZ study. However, The topline results for the ReThink-ALZ Phase 3 trial are expected to be released by the end of 2024.
投資有風險，願賭服輸。信息分享，YMYD。Good luck and best wishes.
